GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Piotroski F-Score

Nutra Pharma (Nutra Pharma) Piotroski F-Score : 0 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nutra Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Nutra Pharma's Piotroski F-Score or its related term are showing as below:


Nutra Pharma Piotroski F-Score Historical Data

The historical data trend for Nutra Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Piotroski F-Score Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 3.00 2.00 4.00

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 4.00 5.00 6.00 5.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Net Income was 2.169 + 5.013 + -0.646 + 0.577 = $7.11 Mil.
Cash Flow from Operations was -0.234 + -0.258 + -0.285 + -0.165 = $-0.94 Mil.
Revenue was 0.026 + 0.022 + 0.09 + 0.109 = $0.25 Mil.
Gross Profit was -0.039 + 0.008 + 0.03 + 0.068 = $0.07 Mil.
Average Total Assets from the begining of this year (Sep21)
to the end of this year (Sep22) was
(0.835 + 0.78 + 0.776 + 0.757 + 0.691) / 5 = $0.7678 Mil.
Total Assets at the begining of this year (Sep21) was $0.84 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Total Current Assets was $0.46 Mil.
Total Current Liabilities was $16.15 Mil.
Net Income was -2.034 + -34.016 + 3.362 + 15.433 = $-17.26 Mil.

Revenue was 0.015 + 0.022 + 0.03 + 0.019 = $0.09 Mil.
Gross Profit was -0.01 + 0.016 + 0.021 + 0.01 = $0.04 Mil.
Average Total Assets from the begining of last year (Sep20)
to the end of last year (Sep21) was
(0.302 + 0.302 + 0.435 + 0.65 + 0.835) / 5 = $0.5048 Mil.
Total Assets at the begining of last year (Sep20) was $0.30 Mil.
Long-Term Debt & Capital Lease Obligation was $0.68 Mil.
Total Current Assets was $0.57 Mil.
Total Current Liabilities was $23.78 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nutra Pharma's current Net Income (TTM) was 7.11. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nutra Pharma's current Cash Flow from Operations (TTM) was -0.94. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep21)
=7.113/0.835
=8.51856287

ROA (Last Year)=Net Income/Total Assets (Sep20)
=-17.255/0.302
=-57.13576159

Nutra Pharma's return on assets of this year was 8.51856287. Nutra Pharma's return on assets of last year was -57.13576159. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Nutra Pharma's current Net Income (TTM) was 7.11. Nutra Pharma's current Cash Flow from Operations (TTM) was -0.94. ==> -0.94 <= 7.11 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0.152/0.7678
=0.19796822

Gearing (Last Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=0.68/0.5048
=1.34706815

Nutra Pharma's gearing of this year was 0.19796822. Nutra Pharma's gearing of last year was 1.34706815. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep22)=Total Current Assets/Total Current Liabilities
=0.462/16.148
=0.02861035

Current Ratio (Last Year: Sep21)=Total Current Assets/Total Current Liabilities
=0.572/23.775
=0.02405889

Nutra Pharma's current ratio of this year was 0.02861035. Nutra Pharma's current ratio of last year was 0.02405889. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Nutra Pharma's number of shares in issue this year was 15597.614. Nutra Pharma's number of shares in issue last year was 12670.053. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.067/0.247
=0.27125506

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.037/0.086
=0.43023256

Nutra Pharma's gross margin of this year was 0.27125506. Nutra Pharma's gross margin of last year was 0.43023256. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep21)
=0.247/0.835
=0.29580838

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep20)
=0.086/0.302
=0.28476821

Nutra Pharma's asset turnover of this year was 0.29580838. Nutra Pharma's asset turnover of last year was 0.28476821. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nutra Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Nutra Pharma  (OTCPK:NPHC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Nutra Pharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutra Pharma (Nutra Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired 04-19-2018